Liquidia Sees 60% Q1 Revenue Surge to $18.4M, Expands Facility 40%
Liquidia posted Q1 2026 revenue of $18.4 million, up 60% year-over-year, driven by increased Yutrepia prescriptions and license fees. The company also announced a 40% capacity expansion at its Morrisville facility and advanced its LIQ861 pulmonary pipeline into Phase 3 enrollment.
1. Q1 2026 Financial Results
Liquidia delivered Q1 revenue of $18.4 million, a 60% increase from $11.5 million in Q1 2025. The company reported a net loss of $6.2 million, or $0.12 per share, reflecting increased SG&A investments to support commercialization.
2. Capacity Expansion
Management announced a 40% boost in manufacturing capacity at its Morrisville, NC facility, funded by a $15 million equity raise completed in April 2026. This expansion is expected to support up to 5,000 additional patient treatments annually by mid-2027.
3. Pipeline Advancement
Liquidia confirmed dosing initiation in its Phase 3 trial of LIQ861 for pulmonary arterial hypertension, targeting full enrollment by Q4 2026. The company also plans to file an IND for its inhaled mRNA platform in late 2026.